Dr Stein spoke about prophage vs CLDX.
i see 5's in the near future.
Sentiment: Strong Buy
AGENUS Rocket moving to the launch PAD. Countdown sequence starting:
Slide 5 & 97
Internal discovery plus Agenus
epacadostat IDO1 Multiple tumor types
Multiple combinations expected to begin PoC clinical trials in 2H 2015 -- Similar trial designs will be utilized within the Agenus alliance to rapidly evaluate mono- and combination therapy to leverage modulation of the tumor microenvironment
Tumor pharmacodynamics: INCB54329 Synergizes with JAK1 Inhibition in Myeloma
INCB052793 + INCB054329
King added AGEN to the Watchlist. Agenus Inc. (AGEN:NASDAQ) “has a broad portfolio of immune checkpoint modulators, a great scientific platform, and partnerships for several of its clinical and preclinical therapies. Heat shock protein vaccines for glioblastoma multiforme and use in combination therapies are in Phase 2, and “investors can expect one or more clinical candidates to be declared in 2016,” King said.
"In a pivotal phase-3 trial led by a Stanford University School of Medicine investigator, a novel drug for rheumatoid arthritis substantially reduced symptoms and improved daily physical functioning in patients for whom other therapies had failed.
A study summarizing the 24-week randomized, double-blind, placebo-controlled trial, which was carried out at 178 centers in 24 countries and involved more than 500 adults who had been living with the painful autoimmune condition for 14 years on average, will be published in the March 31, 2016 issue of The New England Journal of Medicine.
"This is the first drug to demonstrate meaningful clinical benefit in patients who've failed virtually every other commercial drug for rheumatoid arthritis," said Mark Genovese, MD, professor of immunology and rheumatology and the study's lead author. The senior author was Josef Smolen, MD, of the Medical University of Vienna, in Austria.
The drug, baricitinib, belongs to a new category of small-molecule drugs, available in pill form, called Janus-kinase inhibitors. They work by interfering with intracellular enzymes whose signaling action is necessary for various inflammatory substances in the body to be effective.
Pain, stiffness and swelling
Rheumatoid arthritis is a progressive, inflammatory autoimmune disease affecting about 1.5 percent of the population of developed countries. It most commonly manifests between the ages of 30 and 60. It causes pain, stiffness, swelling and eventual destruction of multiple joints, typically smaller ones such as in the hands and feet. About three of every four people with the disease are women. The reasons for this gender skew are unknown."
Dec-2015 ($4.50 - $5.15 PPS) then July -2015 ($8.10 - $9.49)..... interesting
Sentiment: Strong Buy
Innovative and Diversified Research and Development Portfolio
Sentiment: Strong Buy
Coherus Announces the Appointment of Jim Daly, Executive Chairman, Commercial Advisory Committee
California State Teachers Retirement System boosted its position in Agenus by 1.8% in the fourth quarter. the company’s stock valued at $643,000 after buying an additional 2,501 shares during the period.
how much will they and all others in the RA field lose to: INCY and Eli Lilly and Company ... Lilly will lead launch and global commercialization efforts for baricitinib in RA.
Sentiment: Strong Buy
Wells Fargo & Company MN increased its position in Agenus Inc (NASDAQ:AGEN) by 177.2% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 332,554 shares of the company’s stock after buying an additional 212,599 shares during the period. Wells Fargo & Company MN owned about 0.39% of Agenus worth $1,510,000 as of its most recent SEC filing.
I won't be INCY and will have 0% impact on incy. Incy is exhausted! It has been dead $ for 5 months now and will continue to be dead $ for the balance of 2016. The PhD's / Dr's / MD's all have egos beyond our wildest imagination. It was written within the walls of INCY: The success of a research project is defined by how long it lasts! INCY wants to study opportunities to death -- they do not know who to mobilize from study to pilot to produce. All they are use to is OPM (others people money). BB needs to light a fire under management and curtail all stock options.
Problem with INCY it has no activist. VRX has Bill Ackman. CHK @ $4.70 up from $1.50 has Carl Icahn, FCX @ $9.55 up from $3.52 also has Carl Icahn. BAC @ $13.79 up from $5.75 has Warren Buffett. Who is INCY's activist? No one, other than the boobsie twins: Madeoff Maddie and MtTurdinu. Oh, I forgot, Jacosa -- the ex INCY employee or current employee of Incy's specialty pharmacy outlet! Don't let the SEC know about this. BB or Wellington needs "active" voices for INCY because INCY's PR dept. is non-existant. INCY's PR (IR) dept. reminds me of the commercials on the MAYTAG repair man, sleeping with his feet up on the desk in every commercial.
CTI BioPharma announced that the Company received written communication from the FDA on February 4, 2016, that the FDA has placed a partial clinical hold on the clinical studies being conducted under the Company's Investigational New Drug application for pacritinib. This clinical hold impacts part of the clinical work currently being conducted under the IND and will also affect planned clinical trials.
•Under the partial clinical hold, clinical investigators may not enroll new patients or start pacritinib as initial or crossover treatment, and patients not deriving benefit after 30 weeks of pacritinib treatment should stop using pacritinib.
•In addition, the FDA has recommended that the Company make certain modifications of protocols, including modifying all protocols for randomized trials to disallow crossover to pacritinib, provide certain notifications, revise relevant statements in the related investigator's brochure and informed consent documents, and take certain other actions. The Company intends to implement the FDA's recommendations.
•All clinical investigators worldwide have been delivered a notice of the partial clinical hold
Well your response should draw fire from Maddi, $130, no $150, no $200 by Friday. The balloon popped. Now maybe INCY might (huge events need to take place) be $100 (50% premium) if there is a hostile takeover. Awful to re-inflated a popped balloon, INCY remains range bound $65 - $75, watch for the trapdoor to $50's if there are any whiffs of bad news.
Maddi, really in 2 months $150 but now settle for $80's? Really, maybe u should start buyout by Friday @ $100.
have kept you from posting a bit. Loser!
maddy maddy 2 by 4 can't get thru the bathroom door. Boy George u sure r a girly bully. Got any hot tips like $120 by friday? Buy out any day now?